Osteopontin in Cardiovascular Diseases
Unprecedented advances in secondary prevention have greatly improved the prognosis of cardiovascular diseases (CVDs); however, CVDs remain a leading cause of death globally. These findings suggest the need to reconsider cardiovascular risk and optimal medical therapy. Numerous studies have shown tha...
Main Authors: | Kohsuke Shirakawa, Motoaki Sano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/7/1047 |
Similar Items
-
Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study
by: Federico Carbone, et al.
Published: (2022-02-01) -
Neutrophils and Neutrophil Extracellular Traps in Cardiovascular Disease: An Overview and Potential Therapeutic Approaches
by: Kohsuke Shirakawa, et al.
Published: (2022-08-01) -
Osteopontin as a Biomarker in Chronic Kidney Disease
by: Satyesh K. Sinha, et al.
Published: (2023-05-01) -
Elevated osteopontin and IFNy serum levels and increased neutrophil-to-lymphocyte ratio are associated with the severity of symptoms in schizophrenia
by: M. Kovács, et al.
Published: (2022-06-01) -
The pivotal role of osteopontin in UV-induced skin inflammation in a mouse model
by: Haesoo Kim, et al.
Published: (2024-11-01)